Lindahl acted as legal adviser to Senzime AB in connection with the company’s rights issue

Lindahl acted as legal adviser to Senzime AB (publ) in connection with the company’s rights issue, which was resolved by the board of directors on 23 January 2023 and approved at an extraordinary general meeting held on 16 February 2023. The purpose of the rights issue was to support the company’s continued growth. Through the rights issue, the company raised approximately SEK 91.9 million before transaction costs.

Senzime’s shares are listed on Nasdaq Stockholm Main Market. The company develops, manufactures and markets CE- and FDA-approved patient monitoring systems, with the vision of a world without anaesthesia- and respiratory-related complications.

Lindahl’s team consisted of Helena Lindbäck, Michaela Larsson, Erika Svensson and Mattias Prage.

Capital Markets | Public M&A

Lindahl assists companies with stock market listings, issuances, and regulations within the securities market.

Life Sciences

Legal advice in pharmaceuticals, medical technology, and the healthcare sector.

Related cases & articles